(Q40877224)

English

Effects of 4 weeks' administration of pramlintide, a human amylin analogue, on glycaemia control in patients with IDDM: effects on plasma glucose profiles and serum fructosamine concentrations

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Effects of 4 weeks' administration of pramlintide, a human amylin analogue, on glycaemia control in patients with IDDM: effects on plasma glucose profiles and serum fructosamine concentrations (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

0 references

author name string

R G Thompson

1

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

L Pearson

2

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

O G Kolterman

3

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 November 1997

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

40

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

1278-1285

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

https://scigraph.springernature.com/pub.10.1007/s001250050821

0 references

Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1007%2FS001250050821

21 January 2018

Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans

1 reference

https://api.crossref.org/works/10.1007%2FS001250050821

21 January 2018

Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans.

1 reference

https://api.crossref.org/works/10.1007%2FS001250050821

21 January 2018

A novel peptide in the calcitonin gene related peptide family as an amyloid fibril protein in the endocrine pancreas

1 reference

https://api.crossref.org/works/10.1007%2FS001250050821

21 January 2018

Reduction of Postprandial Hyperglycemia in Subjects With IDDM by Intravenous Infusion of AC137, a Human Amylin Analogue

1 reference

https://api.crossref.org/works/10.1007%2FS001250050821

21 January 2018

Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM.

1 reference

https://api.crossref.org/works/10.1007%2FS001250050821

21 January 2018

A sharper Bonferroni procedure for multiple tests of significance

1 reference

https://api.crossref.org/works/10.1007%2FS001250050821

21 January 2018

Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial

1 reference

https://api.crossref.org/works/10.1007%2FS001250050821

21 January 2018

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1007%2FS001250050821

21 January 2018

Disordered gastric motor function in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS001250050821

21 January 2018

Highly variable gastric emptying in patients with insulin dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS001250050821

21 January 2018

Gastric emptying in diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS001250050821

21 January 2018

Adverse events and their association with treatment regimens in the diabetes control and complications trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/9389419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose-response for glucagonostatic effect of amylin in rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/9389419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin

1 reference

https://pubmed.ncbi.nlm.nih.gov/9389419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Amylin concentrations and glucose control

1 reference

https://pubmed.ncbi.nlm.nih.gov/9389419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S001250050821

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40877224&oldid=1909420740"